The phase I BLOOM trial reported that 33% (n = 7/21) of pretreated, EGFR-mutant, advanced LUAD patients with leptomeningeal metastases responded to osimertinib 160 mg daily and achieved an intracranial DCR of 76% (n = 16/21).37,38 Only 2 patients with leptomeningeal disease were included in this present trial. Here, EGFR is linked to leptomeningeal metastasis.